Tom P Freeman1, Peggy van der Pol2, Wil Kuijpers3, Jeroen Wisselink3, Ravi K Das4, Sander Rigter2, Margriet van Laar2, Paul Griffiths5, Wendy Swift6, Raymond Niesink2, Michael T Lynskey1. 1. National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK. 2. Trimbos Institute, Netherlands Institute of Mental Health and Addiction,Utrecht,the Netherlands. 3. Stichting Informatievoorziening Zorg, National Alcohol and Drugs Information System,Houten,the Netherlands. 4. Clinical Psychopharmacology Unit,University College London,London,UK. 5. European Monitoring Centre for Drugs and Drug Addiction,Portugal. 6. National Drug and Alcohol Research Centre, UNSW Australia,Sydney,NSW,Australia.
Abstract
BACKGROUND: The number of people entering specialist drug treatment for cannabis problems has increased considerably in recent years. The reasons for this are unclear, but rising cannabis potency could be a contributing factor. METHODS: Cannabis potency data were obtained from an ongoing monitoring programme in the Netherlands. We analysed concentrations of δ-9-tetrahydrocannabinol (THC) from the most popular variety of domestic herbal cannabis sold in each retail outlet (2000-2015). Mixed effects linear regression models examined time-dependent associations between THC and first-time cannabis admissions to specialist drug treatment. Candidate time lags were 0-10 years, based on normative European drug treatment data. RESULTS: THC increased from a mean (95% CI) of 8.62 (7.97-9.27) to 20.38 (19.09-21.67) from 2000 to 2004 and then decreased to 15.31 (14.24-16.38) in 2015. First-time cannabis admissions (per 100 000 inhabitants) rose from 7.08 to 26.36 from 2000 to 2010, and then decreased to 19.82 in 2015. THC was positively associated with treatment entry at lags of 0-9 years, with the strongest association at 5 years, b = 0.370 (0.317-0.424), p < 0.0001. After adjusting for age, sex and non-cannabis drug treatment admissions, these positive associations were attenuated but remained statistically significant at lags of 5-7 years and were again strongest at 5 years, b = 0.082 (0.052-0.111), p < 0.0001. CONCLUSIONS: In this 16-year observational study, we found positive time-dependent associations between changes in cannabis potency and first-time cannabis admissions to drug treatment. These associations are biologically plausible, but their strength after adjustment suggests that other factors are also important.
BACKGROUND: The number of people entering specialist drug treatment for cannabis problems has increased considerably in recent years. The reasons for this are unclear, but rising cannabis potency could be a contributing factor. METHODS: Cannabis potency data were obtained from an ongoing monitoring programme in the Netherlands. We analysed concentrations of δ-9-tetrahydrocannabinol (THC) from the most popular variety of domestic herbal cannabis sold in each retail outlet (2000-2015). Mixed effects linear regression models examined time-dependent associations between THC and first-time cannabis admissions to specialist drug treatment. Candidate time lags were 0-10 years, based on normative European drug treatment data. RESULTS:THC increased from a mean (95% CI) of 8.62 (7.97-9.27) to 20.38 (19.09-21.67) from 2000 to 2004 and then decreased to 15.31 (14.24-16.38) in 2015. First-time cannabis admissions (per 100 000 inhabitants) rose from 7.08 to 26.36 from 2000 to 2010, and then decreased to 19.82 in 2015. THC was positively associated with treatment entry at lags of 0-9 years, with the strongest association at 5 years, b = 0.370 (0.317-0.424), p < 0.0001. After adjusting for age, sex and non-cannabis drug treatment admissions, these positive associations were attenuated but remained statistically significant at lags of 5-7 years and were again strongest at 5 years, b = 0.082 (0.052-0.111), p < 0.0001. CONCLUSIONS: In this 16-year observational study, we found positive time-dependent associations between changes in cannabis potency and first-time cannabis admissions to drug treatment. These associations are biologically plausible, but their strength after adjustment suggests that other factors are also important.
Entities:
Keywords:
addiction; cannabis; drug treatment; mental health; potency; psychosis; δ-9-tetrahydrocannabinol
Authors: Brooke J Arterberry; Hayley Treloar Padovano; Katherine T Foster; Robert A Zucker; Brian M Hicks Journal: Drug Alcohol Depend Date: 2018-12-17 Impact factor: 4.492
Authors: Tom P Freeman; Chandni Hindocha; Gianluca Baio; Natacha D C Shaban; Emily M Thomas; Danica Astbury; Abigail M Freeman; Rachel Lees; Sam Craft; Paul D Morrison; Michael A P Bloomfield; Dominic O'Ryan; Jane Kinghorn; Celia J A Morgan; Ali Mofeez; H Valerie Curran Journal: Lancet Psychiatry Date: 2020-07-28 Impact factor: 27.083
Authors: Jessica L Bourdon; Meredith W Francis; Lena Jia; Chenxue Liang; Helen I Robinson; Richard A Grucza Journal: J Subst Abuse Treat Date: 2021-06-11
Authors: Diego Quattrone; Laura Ferraro; Giada Tripoli; Caterina La Cascia; Harriet Quigley; Andrea Quattrone; Hannah E Jongsma; Simona Del Peschio; Giusy Gatto; Charlotte Gayer-Anderson; Peter B Jones; James B Kirkbride; Daniele La Barbera; Ilaria Tarricone; Domenico Berardi; Sarah Tosato; Antonio Lasalvia; Andrei Szöke; Celso Arango; Miquel Bernardo; Julio Bobes; Cristina Marta Del Ben; Paulo Rossi Menezes; Pierre-Michel Llorca; Jose Luis Santos; Julio Sanjuán; Andrea Tortelli; Eva Velthorst; Lieuwe de Haan; Bart P F Rutten; Michael T Lynskey; Tom P Freeman; Pak C Sham; Alastair G Cardno; Evangelos Vassos; Jim van Os; Craig Morgan; Ulrich Reininghaus; Cathryn M Lewis; Robin M Murray; Marta Di Forti Journal: Psychol Med Date: 2020-03-18 Impact factor: 7.723